Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02684708Phase 3Completed

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Role: collaborator

NCT01088750Phase 4Completed

Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Role: collaborator

NCT00433459Phase 3Completed

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Role: collaborator

All 3 trials loaded